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Unscheduled cell cycle reentry of postmitotic neurons has been described in cases of mild cognitive impairment
(MCI) and Alzheimer’s disease (AD) and may form a basis for selective neuronal vulnerability during disease
progression. In this regard, the multifunctional protein regulator of cell cycle (RGCC) has been implicated in
driving G1/S and G2/M phase transitions through its interactions with cdc/cyclin-dependent kinase 1 (cdk1) and
is induced by p53, which mediates apoptosis in neurons. We tested whether RGCC levels were dysregulated in
frontal cortex samples obtained postmortem from subjects who died with a clinical diagnosis of no cognitive
impairment (NCI), MCI, or AD. RGCC mRNA and protein levels were upregulated by ~50%–60% in MCI
and AD compared to NCI, and RGCC protein levels were associated with poorer antemortem global cognitive
performance in the subjects examined. To test whether RGCC might regulate neuronal cell cycle reentry and
apoptosis, we differentiated neuronotypic PC12 cultures with nerve growth factor (NGF) followed by NGF
withdrawal to induce abortive cell cycle activation and cell death. Experimental reduction of RGCC levels
increased cell survival and reduced levels of the cdk1 target cyclin B1. RGCC may be a candidate cell cycle
target for neuroprotection during the onset of AD.
Key words: Mild cognitive impairment (MCI); Alzheimer’s disease (AD); Cell cycle;
Regulator of cell cycle (RGCC); Nerve growth factor (NGF); Apoptosis

INTRODUCTION
Several lines of evidence suggest that cell cycle reactivation occurs in postmitotic neurons in Alzheimer’s
disease (AD) and its putative prodromal stage, mild cognitive impairment (MCI). The AD brain is characterized
by neuronal expression of cell cycle regulatory proteins1–3
and DNA replication4–6, whereas we have demonstrated
the presence of the cell cycle proteins proliferating cell
nuclear antigen (PCNA), cyclin D1, and cyclin B1 in neurons in vulnerable brain regions in subjects with MCI7.
Mechanistically, a link has been established between
unscheduled cell cycle reentry and neuronal apoptosis, suggesting a pathogenic mechanism for neuronal
selective vulnerability8–13. Moreover, the activation of
several cell cycle-related kinases, including cdc2/cyclindependent kinase 1 (cdk1), cdc2-like kinase, cdk2, and
cdk5, has been shown to phosphorylate tau and promote
tau aggregation14–17.

The mechanisms underlying aberrant neuronal cell
cycle reentry during the onset of AD have not been firmly
established, but various stressors such as DNA damage
and neurotrophin dysregulation have been proposed18–22.
Notably, the tumor suppressor protein p53, which induces
cell cycle arrest and DNA repair in damaged proliferating cells, facilitates apoptosis when the neuronal milieu
is presented with toxic insults23–25. Although the link
between p53, cell cycle dysregulation, and apoptosis is
unclear, p53 induces the expression of the multifunctional protein regulator of cell cycle (RGCC)26,27, which
is highly expressed in many cancerous tissues28. RGCC
has been shown to either induce S phase entry and mitosis or promote differentiation in nonneuronal cells, which
appears to be context dependent27–32. Whether RGCC dysfunction might represent a novel pathway linking aberrant cell cycle activation and apoptosis in neurons during
the progression of AD remains undetermined. In the
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present study, we measured RGCC mRNA and protein
levels in frontal cortex samples obtained postmortem
from individuals who died with an antemortem diagnosis
of no cognitive impairment (NCI), MCI, or AD. We also
tested whether RGCC expression impacted cell survival
in an in vitro experimental paradigm for neuronal cell
cycle-induced apoptosis.

clinical, and neuropathological characteristics of the subjects are summarized in Table 1. Details of cognitive
evaluations and diagnostic criteria have been extensively
published33–36. Briefly, a team of investigators performed
annual neuropsychological performance testing including the Mini Mental State Exam (MMSE) and 17 additional neuropsychological tests referable to five cognitive
domains: orientation, attention, memory, language, and
perception. A Global Cognitive Score (GCS), consisting
of a composite z-score calculated from this test battery,
was determined for each participant. A board-certified
neurologist with expertise in the evaluation of the elderly
made the clinical diagnosis based on impairments in each
of the five cognitive domains and a clinical examination.
The diagnosis of dementia or AD met recommendations
by the joint working group of the National Institute of

MATERIALS AND METHODS
Subjects
Brain tissues from NCI (n = 14), MCI (n = 11), and
mild/moderate AD (n = 11) cases from both genders
were obtained from participants in the Rush Religious
Orders Study, a longitudinal clinical pathologic study of
aging and AD in elderly Catholic clergy33. Demographic,

Table 1. Clinical, Demographic, and Neuropathological Characteristics by Diagnosis Category
Clinical Diagnosis
Characteristics
Comparison
Age (years) at death
Mean ± SD
Range
Number (%) of males
Years of education
Mean ± SD
Range
Number (%) with ApoE e4 allele
MMSE
Mean ± SD
Range
Global cognitive score
Mean ± SD
Range
Postmortem interval (h)
Mean ± SD
Range
Distribution of Braak scores
0
I/II
III/IV
V/VI
NIA-Reagan diagnosis (likelihood of AD)
No AD
Low
Intermediate
High
CERAD diagnosis
No AD
Possible
Probable
Definite

NCI (n = 14)

MCI (n = 11)

AD (n = 11)

83.9 ± 4.5
76–92
6 (43%)

84.4 ± 5.2
72–91
6 (54%)

86.2 ± 5.1
78–95
6 (54%)

19.1 ± 2.9
15–22
2 (14%)

18.9 ± 4.3
8–24
2 (18%)

14–21
5 (45%)

28.1 ± 0.9
26–29

26.8 ± 2.6
22–30

15.1 ± 7.7
0–27

0.0 ± 0.3
−0.5 to 0.4

−0.37 ± 0.4
−1.2 to 0.3

4.7 ± 2.9
2.2–12.0

6.0 ± 3.3
2.7–13.0

p Value
0.1*

–

0.5†
0.1*

–
–

0.01†
<0.0001*

AD > NCI, MCI
NCI, MCI > AD

<0.0001*

NCI, MCI > AD

−1.8 ± 0.6
−2.8 to −0.7
0.3*
5.4 ± 3.4
2.7–12.0
0.1*

0
5
8
1

0
4
6
1

0
2
6
3

0
6
6
2

0
6
5
0

0
5
5
1

3
3
6
2

4
2
3
2

3
2
5
1

0.2*

0.2*

*Kruskal–Wallis test, with Bonferroni correction for multiple comparisons.
†Fisher’s exact test, with Bonferroni correction for multiple comparisons.

Pairwise

–
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Neurologic and Communicative Disorders and Stroke/AD
and Related Disorders Association (NINCDS/ADRDA)37.
The MCI population was defined as subjects who exhibited impairment on neuropsychological testing but did
not meet the criteria for AD or dementia. These criteria for MCI are consistent with those used by others in
the field38.
Tissue samples were accrued as previously reported34,39,40.
At autopsy, tissue from one hemisphere was immersion fixed in 4% paraformaldehyde (Sigma-Aldrich,
St. Louis, MO, USA) in 0.1 M phosphate buffer (pH
7.2) for 24–72 h at 4°C. Tissue slabs from the opposite
hemisphere were frozen at −80°C prior to collection of
frontal cortex samples for quantitative polymerase chain
reaction (qPCR) and biochemical analysis. A series of
fixed tissue sections were prepared for neuropathological evaluation including visualization and quantitation
of neocortical and hippocampal amyloid plaques and
neurofibrillary tangles (NFTs) using antibodies directed
against the Ab peptide (Ab; 4G8; Covance, Princeton,
NJ, USA), tau (PHF1; a gift from Dr. Peter Davies)33,40,
as well as thioflavine-S (Sigma-Aldrich) histochemistry
and a modified Bielschowsky silver stain (components
from Fisher Scientific, Pittsburgh, PA, USA). Additional
sections were stained for Lewy bodies using antibodies
directed against ubiquitin and a-synuclein. Exclusion
criteria included argyrophilic grain disease, frontotemporal dementia, Lewy body disease, mixed dementias,
Parkinson’s disease, stroke, and hippocampal sclerosis.
A board-certified neuropathologist blinded to the clinical diagnosis performed the neuropathological evaluation. Neuropathological criteria were based on National
Institute on Aging (NIA)-Reagan, Consortium to Establish
a Registry for Alzheimer’s Disease (CERAD), and Braak
staging41–43. Amyloid burden and apolipoprotein E (ApoE)
genotype were determined for each case as described
previously33,40.
qPCR
Total RNA from frozen frontal cortex (Brodmann area
10) samples was extracted using guanidine-isothiocyanate
lysis (PureLink; Ambion, Waltham, MA, USA), and RNA
integrity and concentration were verified using Bioanalysis
(Agilent Technologies, Santa Clara, CA, USA). Samples
were assayed on a real-time (RT)-PCR cycler (ABI 7500;
Applied Biosystems, Foster City, CA, USA) in 96-well
optical plates as described previously44–47. qPCR was
performed using TaqMan hydrolysis probe primer sets
(Applied Biosystems) specific for amplification of the following human transcripts: rgcc (probe set Hs00204129_
m1), tumor protein p53 (tp53; Hs01034249_m1), and
cdk1 (Hs00938777_m1). A primer set specific for human
glyceraldehyde 3-phosphate dehydrogenase (gapdh)
(Hs02758991_g1) was used as a control housekeeping
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transcript. For PC12 cell culture experiments (see below),
total RNA was extracted and assayed as described above
using primers specific for rat cyclin b1 (ccnb1; probe set
Rn01494180_g1; Applied Biosystems) and rat gapdh
(Rn01775763_g1). The D–D Ct (ddCT) method was
employed to determine relative levels of each amplicon44–46,48. Variance component analyses revealed relatively low levels of within-case variability, and the average value of the triplicate qPCR products from each case
was used in subsequent analyses. Alterations in PCR
product synthesis were analyzed by one-way analysis of
variance (ANOVA) with Bonferroni correction for post
hoc comparison. The level of statistical significance was
set at a = 0.05 (two sided).
Western Blotting
Frozen frontal cortex tissue samples from the same
cases used for qPCR were sonicated in ice-cold homogenization buffer [20 mM Tris, 1 mM ethylene glycolbis(b-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA),
1 mM ethylenediaminetetraacetic acid (EDTA), 10%
sucrose, pH 7.4] containing protease inhibitors (2 mg/
ml leupeptin, 0.01 U/ml aprotinin, 1 mg/ml pepstatin A,
1 mg/ml antipain, 2.5 mg/ml chymostatin, 10 mM benzamidine, 0.1 mM PMSF, 0.4 mg/ml TPCK, 0.4 mg/ml
TLCK, 0.4 mg/ml soybean trypsin inhibitor, 0.1 mM
sodium fluoride, and 0.1 mM sodium orthovanadate). All
chemicals were purchased from Sigma-Aldrich. Samples
were prepared by centrifugation at 100 ´ g for 10 min at
4°C. The protein concentration of the resulting S1 supernatant was determined by the Bradford method (Bio-Rad,
Hercules, CA, USA), which uses bovine serum albumin
(BSA) as the protein standard. Sample proteins from the
S1 fraction were denatured in sodium dodecyl sulfate
(SDS; Fisher Scientific) loading buffer to a final concentration of 5 mg/ml. Proteins (25 µg/sample) were separated by SDS polyacrylamide gel electrophoresis (10%;
Lonza, Basel, Switzerland), transferred to Immobilon-FL
membranes (Millipore, Billerica, MA, USA), blocked in
Tris-buffered saline (pH 7.4) containing 0.1% Tween 20
(Fisher Scientific) and 2% nonfat milk, and then incubated overnight at 4°C with rabbit polyclonal antiserum to
RGCC (1:500; Novus Biologicals, Littleton, CO, USA).
Blots were then incubated for 1 h with near-infraredlabeled goat anti-rabbit immunoglobulin G (IgG) secondary antiserum (IRDye 680LT; 1:10,000; Licor, Lincoln,
NE, USA) and analyzed on an Odyssey imaging system
(Licor). Following imaging, the membranes were stripped
and reprobed with a mouse monoclonal b-actin antibody
(1:20,000; Millipore) overnight followed by a 1-h incubation with near-infrared-labeled goat anti-mouse IgG
secondary antiserum (IRDye 680LT; 1:10,000; Licor) and
Odyssey imaging. Signals for RCGG were normalized to
b-actin for quantitative analysis34,47,49.
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PC12 Cell Culture
PC12 cultures (a gift of Dr. Richard Burry, Ohio State
University, Columbus, OH, USA) were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% horse serum (Gibco, Grand Island, NY,
USA), 5% FetalClone I bovine serum (Hyclone, Logan,
UT, USA), and 1% penicillin/streptomycin (Gibco).
Cultures were plated at 10 K/cm2 onto Matrigel-coated
dishes (1%; Collaborative Biomedical; Becton Dickinson,
Frankin Lakes, NJ, USA) in DMEM with 1.5% serum.
PC12 cultures were grown for 1 week in the presence of
400 pm (~50 ng/ml) mouse 7S nerve growth factor (NGF;
Alomone Labs, Jerusalem, Israel). Media were replaced
on days 3 and 5 in vitro. On day 7, PC12 cells were rinsed
and incubated with 50 nM RGCC or scrambled siRNA
(Origene, Rockville, MD, USA)/1% Lipofectamine
RNAiMAX (Life Technologies, Carlsbad, CA, USA) in
OptiMEM (Gibco)/400 pm NGF for 18 h48, then rinsed
and exchanged into DMEM/1.5% serum without NGF
for 48 h. Cultures were assayed for cell viability using the
LIVE/DEAD assay (Thermo Fisher Scientific, Waltham,
MA, USA). Sister cultures were analyzed for cyclin B1
(ccnb1) expression, as described above.
Statistical Analysis
Demographic variables (Table 1) were compared among
clinical diagnostic groups by Kruskal–Wallis or Fisher’s
exact tests with Bonferroni correction for pairwise comparisons. Transcript levels (qPCR), protein levels (Western
blotting), and cell viability measures were compared
among groups by one-way ANOVA with Bonferroni post
hoc testing. The level of statistical significance was set at
p < 0.05. RGCC protein levels across diagnostic groups
were tested for associations with clinical and pathological
variables using Spearman rank correlations. The level of
statistical significance was set at p < 0.01.
RESULTS
Subject Demographics
The clinical diagnostic groups did not differ by age,
gender, years of education, or postmortem interval
(Table 1). There were significantly more subjects with an
ApoE 4 allele in the AD (45%) group than in the NCI
(14%) or MCI (18%) group. AD cases had significantly
lower MMSE scores compared to both NCI and MCI
( p < 0.001), whereas the latter two groups did not differ
statistically (Table 1). GCS z-scores were significantly
lower in the AD compared to the NCI and MCI cases
( p < 0.0001). Subjects in the different clinical diagnostic
groups displayed considerable overlap with respect to
pathological diagnostic criteria. Pathological examination revealed that 64% of NCI, 64% of MCI, and 82% of
AD cases were classified as Braak stages III–VI. Using

Figure 1. p53 (tp53) and protein regulator of cell cycle (rgcc) gene expression levels are increased in mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Box plots
show relative expression levels of (A) tp53, (B) rgcc, and (C) cdc/cyclin-dependent kinase 1 (cdk1) normalized to glyceraldehyde 3-phosphate dehydrogenase (gapdh) levels
(mean ± max/min; arbitrary units) in total RNA derived from no cognitive impairment (NCI), MCI, and AD cases. *p < 0.05 versus NCI, via one-way analysis of variance (ANOVA)
with Bonferroni post hoc comparisons.
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the NIA-Reagan criteria, 57% of NCI, 45% of MCI, and
55% of AD cases were classified as intermediate to high
likelihood of AD (Table 1). For CERAD diagnosis, 57%
of NCI, 45% of MCI, and 55% of AD cases received a
diagnosis of probable/definite AD. Statistical analysis did
not reveal any differences in pathology among the NCI,
MCI, and AD groups.
RCGG Expression Levels in MCI and AD
qPCR analysis was performed to quantify RGCC
(rgcc), p53 (tp53), and CDK1 (cdk1) gene expression
levels in frozen frontal cortex tissue samples accrued
from NCI, MCI, and AD subjects (Fig. 1). A significant
~55%–60% increase in rgcc transcript levels was measured in MCI compared to NCI cases ( p < 0.05), whereas
rgcc levels were upregulated by ~50% in AD compared
to NCI ( p < 0.05) (Fig. 1A). By contrast, tp53 expression
levels were significantly increased by ~55%–60% in MCI
and AD compared to NCI ( p < 0.05) (Fig. 1B), whereas
there were no differences in cdk1 expression across the
diagnostic groups (Fig. 1C).
To test whether RCGG protein levels were also upregulated in the MCI and AD cases, quantitative Western
blotting was performed on tissue extracts from the same
cases (Fig. 2). RGCC immunoreactivity (~15-kDa band)
was higher in the MCI and AD frontal cortex compared
to NCI (Fig. 2A). Quantitative analysis of the Western
blots showed that normalized RGCC protein levels were
significantly increased by ~50%–55% in MCI and AD
( p < 0.05). Spearman rank correlations showed no association between RGCC protein levels and age, gender, PMI,
or ApoE status (data not shown). By contrast, increased
RGCC protein levels were associated with poorer cognitive performance as measured by the MMSE (r = 0.39,
p = 0.002) and GCS (r = 0.43, p = 0.005), but not with Braak,
NIA-Reagan, or CERAD neuropathological criteria.
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Inhibition of RGCC Protects PC12 Cells From Nerve
Growth Factor Withdrawal
Neuronotypic differentiation of rat PC12 cells with
NGF, followed by NGF deprivation in low/no serum,
results in aberrant cell cycle entry and apoptosis8,50–53.
In order to assess whether RGCC might play a role in
neuronal apoptosis related to cell cycle reentry, we differentiated PC12 cells and then treated the cultures with
rgcc-specific siRNA or scrambled control siRNA prior
to NGF withdrawal (Fig. 3). There was an overall ~75%
decrease in the cell survival of PC12 cultures subjected
to NGF withdrawal compared to cultures maintained on
NGF (p < 0.01). By contrast, rgcc downregulation rescued the PC12 cultures from NGF deprivation, resulting
in an ~25% decrease in cell survival compared to NGFmaintained cultures (Fig. 3A). To assess the extent of
cell cycle activation in the cultures, we used qPCR to
measure expression levels of cyclin b1 (ccnb1), a CDK1
binding partner that is downregulated during NGFinduced differentiation and upregulated during NGF
withdrawal and apoptosis of PC12 cells54,55. There was
an overall ~80% increase in cyclin B1 levels in PC12
cultures subjected to NGF withdrawal compared to cultures maintained on NGF (p < 0.05). By contrast, rgcc
downregulation prevented cyclin B1 upregulation during NGF deprivation (Fig. 3B).
DISCUSSION
For over two decades, the concept of “abortive mitosis” has been noted as a cellular mechanism of apoptosis
during development and neuronal cell death in neurodegenerative disease3,56,57. With respect to AD, it has been
proposed that deleterious events such as the loss of neurotrophic support needed to maintain terminal differentiation, or neuronal DNA damage from oxidative stress,
result in the transition from a quiescent G0 cell cycle

Figure 2. Regulator of cell cycle (rgcc) protein levels are increased in mild cognitive impairment (MCI) and Alzheimer’s disease
(AD). (A) Representative Western blot shows greater RCGG immunoreactivity (~15 kDa) in tissue extracts derived from MCI and AD
cases compared to no cognitive impairment (NCI) cases; levels of b-actin were equivalent across samples. (B) Box plots show relative
quantitative measurements of RGCC immunoreactivity normalized to b-actin signals (mean ± max/min; arbitrary units) in the three
diagnostic groups. *p < 0.05 versus NCI, via one-way analysis of variance (ANOVA) with Bonferroni post hoc comparisons.
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stage into an unscheduled attempt at DNA replication
and mitosis4,7,18–20. The consequent loss of genomic and
cellular homeostasis ultimately triggers programmed
cell death3,58,59. Moreover, the activation of several cell
cycle kinases, normally under tight regulatory control
in postmitotic neurons, can lead to tau hyperphosphorylation and aggregation into NFTs14–17. Hence, the cell
cycle continues to represent a viable target for diseasemodifying therapies for AD21,58,59. Here we provide evidence that the cell cycle regulatory protein RGCC is
upregulated in MCI and AD, correlates with global cognitive decline, and may be involved in facilitating aberrant cell cycle reentry induced by neurotrophin loss in
differentiated neurons, suggesting that RGCC may be a
candidate cell cycle target for neuroprotection during the
onset of AD. This report may also add another provocative link to the potential mechanistic interrelationship
between cell transformation in cancer and selective vulnerability in neurodegenerative disease. These diseases
share many molecular pathogenic processes, including
oxidative and inflammatory stress, proteostatic stress,
and metabolic dysregulation21,60–64, and it has been postulated that these pathways lead to either clonal expansion
in proliferating cells or clonal elimination in terminally
differentiated cells such as neurons65.
The functional and mechanistic repertoire of RGCC
activity has not been fully elucidated. It was originally
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discovered as the RGC-32 response gene during complement activation of rat oligodendrocytes26. RGCC physically associates with and activates CDK1, a key kinase
involved in the G1/S and G2/M phase transitions26,29,30.
However, RGCC has also been implicated in diverse
functions such as cellular differentiation, inflammation, vascular remodeling, and insulin resistance32,66–70.
Interestingly, RGCC was identified as a transcriptional
target and mediator of p53 tumor suppression in glioma
cells27. In neurons, the p53 protein possesses multifactorial properties regulating DNA damage, cell cycle
control, and apoptosis71,72. Given the evidence that p53
protein is upregulated and possibly dysregulated due to
structural modifications in MCI and AD73–75, we investigated whether RCGG was also upregulated in these disease stages and whether it could potentially play a role in
neuronal cell cycle dysfunction and/or apoptosis. In this
regard, we validated p53 upregulation74 but also found
that RGCC was upregulated in the frontal cortex in MCI
and AD. By contrast, transcripts encoding the RGCCregulated cell cycle protein CDK1 were stable during
disease progression despite a trend (p = 0.07) for upregulation, consistent with the notion that RGCC regulates
CDK1 activity rather than expression30.
The functional consequences of RGCC upregulation
in MCI and AD subjects are unclear, but its role in cell
cycle activation led us to test whether this upregulation

Figure 3. Regulator of cell cycle (rgcc) inhibition rescues PC12 cells from cell death induced by nerve growth factor (NGF) withdrawal. (A) Bar graph shows relative levels of cell survival as measured by the LIVE/DEAD assay [mean ± standard deviation (SD);
arbitrary units] for PC12 cultures maintained on NGF, deprived of NGF for 48 h, deprived of NGF for 48 h in the presence of rgcc
siRNA, or deprived of NGF for 48 h in the presence of scrambled control siRNA. (B) Bar graph shows relative levels of cyclin b1
(ccnb1) transcript levels as measured by quantitative polymerase chain reaction (qPCR) (mean ± SD; arbitrary units) for PC12 cultures
maintained on NGF, deprived of NGF for 48 h, deprived of NGF for 48 h in the presence of rgcc siRNA, or deprived of NGF for
48 h in the presence of scrambled control siRNA. *p < 0.05; **p < 0.01 versus NGF, via one-way analysis of variance (ANOVA) with
Bonferroni post hoc comparisons.
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could reflect a deleterious event promoting “abortive
mitosis” and neuronal vulnerability. To this end, we
used the PC12 cell culture model as a well-established
system for NGF-mediated neuronotypic differentiation
and NGF withdrawal-mediated cell cycle reactivation
and apoptosis8,50–53. Using rgcc and scrambled sequence
control siRNA, we found that rgcc knockdown protected
PC12 cells from NGF withdrawal and prevented the
upregulation of the CDK1 binding partner cyclin B154,55,
suggesting that RCGG participates in cell cycle reactivation and cell death within the context of deficient neurotrophin signaling.
A central concept underlying the selective vulnerability of neurons in AD is that they are dependent on neurotrophins such as NGF and brain-derived neurotrophic
factor (BDNF) for survival76–78. NGF and BDNF are
derived from proNGF and proBDNF precursor proteins,
and these mature peptides interact with their cognate
high-affinity receptors TrkA and TrkB, respectively, for
prosurvival functions77,79,80. By contrast, proNGF and
proBDNF have higher affinity for the pan neurotrophin
receptor p75NTR and elicit prodeath signals81. Notably, we
found that cortical TrkA protein levels were selectively
reduced in mild AD compared to p75NTR 49, whereas
cortical proNGF levels were elevated in MCI and AD
compared to NCI82. Hence, increased cortical proNGF in
combination with reduced cortical TrkA expression may
result in enhanced binding between proNGF and p75NTR,
potentially shifting away from prosurvival NGF signaling to apoptotic signaling. Likewise, levels of BDNF
and TrkB are decreased in vulnerable brain regions in
MCI and AD39,83. This observation, combined with the
presence of cell cycle proteins within vulnerable brain
regions in MCI and mild AD4,7, suggests that neurotrophin receptor imbalance promotes a loss of neurotrophic
support and unscheduled cell cycle reentry and apoptosis during the prodromal stages of AD. In this regard,
whereas cell cycle abnormalities have been linked to
in vitro and in vivo amyloid and tau pathology84–86, we
did not find a significant association between RGCC
levels and neuropathological diagnostic criteria. This
may be due to the lack of significant differences in Braak,
NIA-Reagan, or CERAD scores among the diagnostic
groups (Table 1). On the other hand, they may suggest
that neurotrophic imbalances affect RGCC and other
cell cycle events independent of plaque or tangle burden.
The extent to which increased RGCC levels denote its
involvement in neurotrophin-mediated mitotic cell death
cascades in the MCI and AD brain is a question for future
study. Furthermore, given the involvement of p53 in
neuronal apoptosis following NGF withdrawal87, it will
be interesting to explore whether a p53-RGCC-CDK1/
cyclin B cascade mediates aberrant cell cycle activation
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in postmitotic neurons. If so, this pathway may present a
novel therapeutic target for disease modification during
the progression of AD.
ACKNOWLEDGMENTS: We are grateful for the altruism of the
Religious Orders Study participants. This study was supported
by the National Institutes of Health (NIH) grants PO1AG14449,
RO1AG043375, R21AG026032, and R21AG042146; the Saint
Mary’s Foundation; Miles for Memories of Battle Creek, MI;
and Barrow Neurological Institute Barrow and Beyond. The
authors declare no conflicts of interest.

REFERENCES
1. Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict the sites of neuronal cell death in Alzheimer’s
disease brain. J Neurosci. 1998;18(8):2801–7.
2. Vincent I, Jicha G, Rosado M, Dickson DW. Aberrant
expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer’s disease brain. J Neurosci. 1997;
17(10):3588–98.
3. Vincent I, Rosado M, Davies P. Mitotic mechanisms in
Alzheimer’s disease? J Cell Biol. 1996;132(3):413–25.
4. Yang Y, Geldmacher DS, Herrup K. DNA replication precedes neuronal cell death in Alzheimer’s disease. J Neurosci. 2001;21(8):2661–8.
5. Bonda DJ, Evans TA, Santocanale C, Llosa JC, Vina J,
Bajic V, Castellani RJ, Siedlak SL, Perry G, Smith MA, Lee
HG. Evidence for the progression through S-phase in the
ectopic cell cycle re-entry of neurons in Alzheimer disease.
Aging (Albany NY) 2009;1(4):382–8.
6. Mosch B, Morawski M, Mittag A, Lenz D, Tarnok A,
Arendt T. Aneuploidy and DNA replication in the normal human brain and Alzheimer’s disease. J Neurosci.
2007;27(26):6859–67.
7. Yang Y, Mufson EJ, Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease. J Neurosci. 2003;23(7):2557–63.
8. Farinelli SE, Greene LA. Cell cycle blockers mimosine,
ciclopirox, and deferoxamine prevent the death of PC12
cells and postmitotic sympathetic neurons after removal of
trophic support. J Neurosci. 1996;16(3):1150–62.
9. Freeman RS, Estus S, Johnson EM Jr. Analysis of cell
cycle-related gene expression in postmitotic neurons:
Selective induction of cyclin D1 during programmed cell
death. Neuron 1994;12(2):343–55.
10. Herrup K, Busser JC. The induction of multiple cell cycle
events precedes target-related neuronal death. Development
1995;121(8):2385–95.
11. Park DS, Levine B, Ferrari G, Greene LA. Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived
sympathetic neurons. J Neurosci. 1997;17(23):8975–83.
12. Frade JM. Unscheduled re-entry into the cell cycle induced
by NGF precedes cell death in nascent retinal neurones.
J Cell Sci. 2000;113(Pt 7):1139–48.
13. Malik B, Currais A, Soriano S. Cell cycle-driven neuronal apoptosis specifically linked to amyloid peptide
Abeta1-42 exposure is not exacerbated in a mouse model
of presenilin-1 familial Alzheimer’s disease. J Neurochem.
2008;106(2):912–6.
14. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson
J, Gaynor K, LaFrancois J, Wang L, Kondo T, Davies P,
Burns M, Veeranna, Nixon R, Dickson D, Matsuoka Y,

700

15.

16.

17.
18.
19.

20.
21.

22.

23.
24.
25.

26.

27.

28.

29.

30.

COUNTS AND MUFSON

Ahlijanian M, Lau LF, Duff K. Cdk5 is a key factor in tau
aggregation and tangle formation in vivo. Neuron 2003;
38(4):555–65.
Baumann K, Mandelkow EM, Biernat J, Piwnica-Worms
H, Mandelkow E. Abnormal Alzheimer-like phosphorylation of tau-protein by cyclin-dependent kinases cdk2 and
cdk5. FEBS Lett. 1993;336(3):417–24.
Bennecib M, Gong CX, Grundke-Iqbal I, Iqbal K. Role of
protein phosphatase-2A and -1 in the regulation of GSK-3,
cdk5 and cdc2 and the phosphorylation of tau in rat forebrain. FEBS Lett. 2000;485(1):87–93.
Paudel HK. Phosphorylation by neuronal cdc2-like protein
kinase promotes dimerization of Tau protein in vitro. J Biol
Chem. 1997;272(45):28328–34.
Arendt T, Bruckner MK, Mosch B, Losche A. Selective cell
death of hyperploid neurons in Alzheimer’s disease. Am J
Pathol. 2010;177(1):15–20.
Silva AR, Santos AC, Farfel JM, Grinberg LT, Ferretti RE,
Campos AH, Cunha IW, Begnami MD, Rocha RM, Carraro
DM, de Braganca Pereira CA, Jacob-Filho W, Brentani H.
Repair of oxidative DNA damage, cell-cycle regulation and
neuronal death may influence the clinical manifestation of
Alzheimer’s disease. PLoS One 2014;9(6):e99897.
Swerdlow RH, Burns JM, Khan SM. The Alzheimer’s disease mitochondrial cascade hypothesis. J Alzheimers Dis.
2010;20(Suppl 2):S265–79.
Webber KM, Raina AK, Marlatt MW, Zhu X, Prat MI,
Morelli L, Casadesus G, Perry G, Smith MA. The cell cycle
in Alzheimer disease: A unique target for neuropharmacology. Mech Ageing Dev. 2005;126(10):1019–25.
Zivkovic L, Spremo-Potparevic B, Siedlak SL, Perry G,
Plecas-Solarovic B, Milicevic Z, Bajic VP. DNA damage in
Alzheimer disease lymphocytes and its relation to premature centromere division. Neurodegener Dis. 2013;12(3):
156–63.
Behrens MI, Lendon C, Roe CM. A common biological mechanism in cancer and Alzheimer’s disease? Curr
Alzheimer Res. 2009;6(3):196–204.
Nakanishi A, Minami A, Kitagishi Y, Ogura Y, Matsuda S.
BRCA1 and p53 tumor suppressor molecules in Alzheimer’s
disease. Int J Mol Sci. 2015;16(2):2879–92.
Vaghefi H, Neet KE. Deacetylation of p53 after nerve
growth factor treatment in PC12 cells as a post-translational
modification mechanism of neurotrophin-induced tumor
suppressor activation. Oncogene 2004;23(49):8078–87.
Badea TC, Niculescu FI, Soane L, Shin ML, Rus H.
Molecular cloning and characterization of RGC-32, a novel
gene induced by complement activation in oligodendrocytes. J Biol Chem. 1998;273(41):26977–81.
Saigusa K, Imoto I, Tanikawa C, Aoyagi M, Ohno K,
Nakamura Y, Inazawa J. RGC32, a novel p53-inducible
gene, is located on centrosomes during mitosis and results
in G2/M arrest. Oncogene 2007;26(8):1110–21.
Vlaicu SI, Cudrici C, Ito T, Fosbrink M, Tegla CA, Rus
V, Mircea PA, Rus H. Role of response gene to complement 32 in diseases. Arch Immunol Ther Exp. (Warsz)
2008;56(2):115–22.
Badea T, Niculescu F, Soane L, Fosbrink M, Sorana H,
Rus V, Shin ML, Rus H. RGC-32 increases p34CDC2
kinase activity and entry of aortic smooth muscle cells into
S-phase. J Biol Chem. 2002;277(1):502–8.
Fosbrink M, Cudrici C, Tegla CA, Soloviova K, Ito T,
Vlaicu S, Rus V, Niculescu F, Rus H. Response gene to

31.

32.

33.

34.

35.

36.

37.

38.

39.

40.

41.
42.

43.

complement 32 is required for C5b-9 induced cell cycle
activation in endothelial cells. Exp Mol Pathol. 2009;86(2):
87–94.
Oram SW, Liu XX, Lee TL, Chan WY, Lau YF. TSPY
potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells. BMC
Cancer 2006;6:154.
Tegla CA, Cudrici CD, Nguyen V, Danoff J, Kruszewski AM,
Boodhoo D, Mekala AP, Vlaicu SI, Chen C, Rus V, Badea
TC, Rus H. RGC-32 is a novel regulator of the T-lymphocyte
cell cycle. Exp Mol Pathol. 2015;98(3):328–37.
Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett
LA, Aggarwal NT, Barnes LL, Fox JH, Bach J. Natural
history of mild cognitive impairment in older persons.
Neurology 2002;59(2):198–205.
Counts SE, Nadeem M, Lad SP, Wuu J, Mufson EJ.
Differential expression of synaptic proteins in the frontal
and temporal cortex of elderly subjects with mild cognitive impairment. J Neuropathol Exp Neurol. 2006;65(6):
592–601.
Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett
DA, Kordower JH. Entorhinal cortex beta-amyloid load in
individuals with mild cognitive impairment. Exp Neurol.
1999;158(2):469–90.
Perez SE, He B, Nadeem M, Wuu J, Scheff SW, Abrahamson
EE, Ikonomovic MD, Mufson EJ. Resilience of precuneus
neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer’s disease. Biol Psychiatry
2015;77(8):693–703.
McKhann G, Drachman D, Folstein M, Katzman R,
Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s
disease: Report of the NINCDS-ADRDA Work Group
under the auspices of Department of Health and Human
Services Task Force on Alzheimer’s Disease. Neurology
1984;34(7):939–44.
Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC,
Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B.
Current concepts in mild cognitive impairment. Arch
Neurol. 2001;58(12):1985–92.
Ginsberg SD, Alldred MJ, Counts SE, Cataldo AM, Neve
RL, Jiang Y, Wuu J, Chao MV, Mufson EJ, Nixon RA, Che
S. Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer’s disease progression. Biol Psychiatry 2010;68(10):885–93.
Mufson EJ, Chen EY, Cochran EJ, Beckett LA, Bennett
DA, Kordower JH. Entorhinal cortex beta-amyloid load in
individuals with mild cognitive impairment. Exp Neurol.
1999;158(2):469–90.
Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol. 1991;82(4):239–59.
Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ,
Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP,
Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR,
Thies B, Trojanowski JQ, Vinters HV, Montine TJ. National
Institute on Aging-Alzheimer’s Association guidelines for
the neuropathologic assessment of Alzheimer’s disease.
Alzheimers Dement. 2012;8(1):1–13.
Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ,
Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L.
The Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology
1991;41(4):479–86.

REGULATOR OF CELL CYCLE IN MCI

44. Alldred MJ, Che S, Ginsberg SD. Terminal continuation
(TC) RNA amplification without second strand synthesis.
J Neurosci Methods 2009;177(2):381–5.
45. Counts SE, He B, Che S, Ikonomovic MD, DeKosky ST,
Ginsberg SD, Mufson EJ. Alpha7 nicotinic receptor upregulation in cholinergic basal forebrain neurons in
Alzheimer disease. Arch Neurol. 2007;64(12):1771–6.
46. Ginsberg SD. Transcriptional profiling of small samples
in the central nervous system. Methods Mol Biol. 2008;
439:147–58.
47. Beck JS, Mufson EJ, Counts SE. Evidence for mitochondrial
UPR gene activation in familial and sporadic Alzheimer’s
disease. Curr Alzheimer Res. 2016;13(6):610–4.
48. Weinberg RB, Mufson EJ, Counts SE. Evidence for a neuroprotective microRNA pathway in amnestic mild cognitive impairment. Front Neurosci. 2015;9:430.
49. Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU,
Mufson EJ. Reduction of cortical TrkA but not p75(NTR)
protein in early-stage Alzheimer’s disease. Ann Neurol.
2004;56(4):520–31.
50. Counts SE, Lah JJ, Levey AI. The regulation of presenilin-1
by nerve growth factor. J Neurochem. 2001;76(3):679–89.
51. Greene LA. Nerve growth factor prevents the death and
stimulates the neuronal differentiation of clonal PC12
pheochromocytoma cells in serum-free medium. J Cell
Biol. 1978;78(3):747–55.
52. Mesner PW, Epting CL, Hegarty JL, Green SH. A timetable
of events during programmed cell death induced by trophic
factor withdrawal from neuronal PC12 cells. J Neurosci.
1995;15(11):7357–66.
53. Bianco MR, Berbenni M, Amara F, Viggiani S, Fragni M,
Galimberti V, Colombo D, Cirillo G, Papa M, Alberghina
L, Colangelo AM. Cross-talk between cell cycle induction and mitochondrial dysfunction during oxidative stress
and nerve growth factor withdrawal in differentiated PC12
cells. J Neurosci Res. 2011;89(8):1302–15.
54. Gao CY, Zelenka PS. Induction of cyclin B and H1
kinase activity in apoptotic PC12 cells. Exp Cell Res.
1995;219(2):612–8.
55. Yan GZ, Ziff EB. NGF regulates the PC12 cell cycle
machinery through specific inhibition of the Cdk kinases
and induction of cyclin D1. J Neurosci. 1995;15(9):
6200–12.
56. Lee S, Christakos S, Small MB. Apoptosis and signal transduction: Clues to a molecular mechanism. Curr Opin Cell
Biol. 1993;5(2):286–91.
57. Ucker DS. Death by suicide: One way to go in mammalian
cellular development? New Biol. 1991;3(2):103–9.
58. Smith MA, Nunomura A, Zhu X, Takeda A, Perry G.
Metabolic, metallic, and mitotic sources of oxidative stress
in Alzheimer disease. Antioxid Redox Signal. 2000;2(3):
413–20.
59. Katsel P, Tan W, Fam P, Purohit DP, Haroutunian V. Cell
cycle checkpoint abnormalities during dementia: A plausible association with the loss of protection against oxidative stress in Alzheimer’s disease [corrected]. PLoS One
2013;8(7):e68361.
60. Audas TE, Audas DE, Jacob MD, Ho JJ, Khacho M,
Wang M, Perera JK, Gardiner C, Bennett CA, Head T,
Kryvenko ON, Jorda M, Daunert S, Malhorta A, TrinkleMulcahy L, Gonzalgo ML, Lee S. Adaptation to stressors
by systemic protein amyloidogenesis. Dev Cell 2016;
39(2):155–168.

701

61. Bennett DA, Leurgans S. Is there a link between cancer and
Alzheimer disease? Neurology 2010;74(2):100–1.
62. Driver JA. Inverse association between cancer and neurodegenerative disease: Review of the epidemiologic and
biological evidence. Biogerontology 2014;15(6):547–57.
63. Harris RA, Tindale L, Cumming RC. Age-dependent metabolic dysregulation in cancer and Alzheimer’s disease.
Biogerontology 2014;15(6):559–77.
64. Vilchez D, Saez I, Dillin A. The role of protein clearance
mechanisms in organismal ageing and age-related diseases.
Nat Commun. 2014;5:5659.
65. Heintz N. Cell death and the cell cycle: A relationship
between transformation and neurodegeneration? Trends
Biochem Sci. 1993;18(5):157–9.
66. An X, Jin Y, Guo H, Foo SY, Cully BL, Wu J, Zeng H,
Rosenzweig A, Li J. Response gene to complement 32, a
novel hypoxia-regulated angiogenic inhibitor. Circulation
2009;120(7):617–27.
67. Cui XB, Luan JN, Ye J, Chen SY. RGC32 deficiency protects against high-fat diet-induced obesity and insulin resistance in mice. J Endocrinol. 2015;224(2):127–37.
68. Tang R, Zhang G, Chen SY. Response gene to complement 32 protein promotes macrophage phagocytosis via
activation of protein kinase C pathway. J Biol Chem.
2014;289(33):22715–22.
69. Xu R, Shang C, Zhao J, Han Y, Liu J, Chen K, Shi W.
Knockdown of response gene to complement 32 (RGC32)
induces apoptosis and inhibits cell growth, migration, and
invasion in human lung cancer cells. Mol Cell Biochem.
2014;394(1–2):109–18.
70. Zhao P, Gao D, Wang Q, Song B, Shao Q, Sun J, Ji C, Li
X, Li P, Qu X. Response gene to complement 32 (RGC-32)
expression on M2-polarized and tumor-associated macrophages is M-CSF-dependent and enhanced by tumorderived IL-4. Cell Mol Immunol. 2015;12(6):692–9.
71. Culmsee C, Mattson MP. p53 in neuronal apoptosis.
Biochem Biophys Res Commun. 2005;331(3):761–77.
72. Lanni C, Racchi M, Memo M, Govoni S, Uberti D. p53 at
the crossroads between cancer and neurodegeneration. Free
Radic Biol Med. 2012;52(9):1727–33.
73. Buizza L, Cenini G, Lanni C, Ferrari-Toninelli G, Prandelli
C, Govoni S, Buoso E, Racchi M, Barcikowska M,
Styczynska M, Szybinska A, Butterfield DA, Memo M,
Uberti D. Conformational altered p53 as an early marker
of oxidative stress in Alzheimer’s disease. PLoS One
2012;7(1):e29789.
74. Cenini G, Sultana R, Memo M, Butterfield DA. Elevated
levels of pro-apoptotic p53 and its oxidative modification by
the lipid peroxidation product, HNE, in brain from subjects
with amnestic mild cognitive impairment and Alzheimer’s
disease. J Cell Mol Med. 2008;12(3):987–94.
75. Perluigi M, Barone E, Di Domenico F, Butterfield DA.
Aberrant protein phosphorylation in Alzheimer disease brain disturbs pro-survival and cell death pathways.
Biochim Biophys Acta 2016;1862(10):1871–82.
76. Altar CA, Cai N, Bliven T, Juhasz M, Conner JM, Acheson
AL, Lindsay RM, Wiegand SJ. Anterograde transport of
brain-derived neurotrophic factor and its role in the brain.
Nature 1997;389(6653):856–60.
77. Counts SE, Mufson EJ. The role of nerve growth factor
receptors in cholinergic basal forebrain degeneration in
prodromal Alzheimer disease. J Neuropathol Exp Neurol.
2005;64(4):263–72.

702

78. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev
Neurosci. 2001;24:1217–81.
79. Mufson EJ, Counts SE, Perez SE, Ginsberg SD.
Cholinergic system during the progression of Alzheimer’s
disease: Therapeutic implications. Expert Rev Neurother.
2008;8(11):1703–18.
80. Barbacid M. Structural and functional properties of the
TRK family of neurotrophin receptors. Ann NY Acad Sci.
1995;766:442–58.
81. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation
of cell survival by secreted proneurotrophins. Science
2001;294(5548):1945–8.
82. Peng S, Wuu J, Mufson EJ, Fahnestock M. Increased
proNGF levels in subjects with mild cognitive impairment
and mild Alzheimer’s disease. J Neuropathol Exp Neurol.
2004;63(6):641–9.
83. Peng S, Wuu J, Mufson EJ, Fahnestock M. Precursor
form of brain-derived neurotrophic factor and mature

COUNTS AND MUFSON

84.
85.

86.

87.

brain-derived neurotrophic factor are decreased in the
pre-clinical stages of Alzheimer’s disease. J Neurochem.
2005;93(6):1412–21.
Bloom GS. Amyloid-beta and tau: The trigger and bullet
in Alzheimer disease pathogenesis. JAMA Neurol. 2014;
71(4):505–8.
Seward ME, Swanson E, Norambuena A, Reimann A,
Cochran JN, Li R, Roberson ED, Bloom GS. Amyloid-beta
signals through tau to drive ectopic neuronal cell cycle reentry in Alzheimer’s disease. J Cell Sci. 2013;126(Pt 5):
1278–86.
Varvel NH, Bhaskar K, Patil AR, Pimplikar SW, Herrup
K, Lamb BT. Abeta oligomers induce neuronal cell cycle
events in Alzheimer’s disease. J Neurosci. 2008;28(43):
10786–93.
Aloyz RS, Bamji SX, Pozniak CD, Toma JG, Atwal J,
Kaplan DR, Miller FD. p53 is essential for developmental
neuron death as regulated by the TrkA and p75 neurotrophin receptors. J Cell Biol. 1998;143(6):1691–703.

